Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL718056 | 1.00 | CNR2 (0.42) | CNR2KDM4EALDH1A1SMN1; SMN2PDCD1LG2 | |
| SCHEMBL715756 | 1.00 | CNR2 (0.42) | CNR2KDM4EALDH1A1SMN1; SMN2PDCD1LG2 | |
| SCHEMBL713498 | 0.88 | CYP1A2 (0.38) | KDM4EALDH1A1SMN1; SMN2PTPN11PDE10A | |
| SCHEMBL716327 | 0.88 | CYP1A2 (0.38) | KDM4EALDH1A1SMN1; SMN2PTPN11PDE10A | |
| SCHEMBL713497 | 0.88 | CYP1A2 (0.38) | KDM4EALDH1A1SMN1; SMN2PTPN11PDE10A | |
| SCHEMBL715705 | 0.83 | KDM4E (0.39) | CNR2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL715103 | 0.83 | KDM4E (0.39) | CNR2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL715104 | 0.83 | KDM4E (0.39) | CNR2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL715249 | 0.82 | HPGD (0.43) | CNR2KDM4EALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL717289 | 0.81 | PIK3CD (0.40) | CNR2KDM4EALDH1A1SMN1; SMN2PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403847-B1 | TRIAZINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-03-02 | — | — | EP | disclosed |
| US-8785628-B2 | Triazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2014-07-22 | — | — | US | disclosed |
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | UCB PHARMA, S.A. (BE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | MAP3K15, PI4KA, MAP3K20 | CNR2 1488/4885KDM4E 2430/4885ALDH1A1 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.